Loading clinical trials...
Loading clinical trials...
Effect of Subcutaneous Immunoglobulin (IgSC) Gammanorm® on the Distribution of IgG Subclasses and on the Humoral Immunity of Patients With Secondary Immunodeficiency.
Conditions
Interventions
Gammanorm
Other Subcutaneous Immunoglobulins
Locations
6
France
CH William Morey Chalon-sur-Saône
Chalon-sur-Saône, France
CHD Vendée
La Roche-sur-Yon, France
CH la Rochelle - Hôpital Saint Louis
La Rochelle, France
CH Orléans
Orléans, France
CHU Bordeaux Centre François Magendie Hopital Haut -Lévêque
Pessac, France
CH Saint Malo
St-Malo, France
Start Date
September 25, 2017
Primary Completion Date
November 22, 2019
Completion Date
November 22, 2019
Last Updated
March 2, 2022
NCT04354129
NCT03730129
Lead Sponsor
Octapharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions